LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $125,093 | +145.3% | 83,395 | +86.4% | 0.00% | +100.0% |
Q3 2022 | $51,000 | -28.2% | 44,733 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $71,000 | -58.2% | 44,733 | -38.0% | 0.00% | -75.0% |
Q1 2021 | $170,000 | +347.4% | 72,194 | +80.1% | 0.00% | +300.0% |
Q3 2020 | $38,000 | -7.3% | 40,083 | -15.0% | 0.00% | 0.0% |
Q2 2020 | $41,000 | – | 47,157 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |